• Product name

    Anti-KMT2A / MLL antibody [EPR22647-8]
    See all KMT2A / MLL primary antibodies
  • Description

    Rabbit monoclonal [EPR22647-8] to KMT2A / MLL
  • Host species

  • Tested applications

    Suitable for: WBmore details
    Unsuitable for: Flow Cyt,ICC/IF,IHC-P or IP
  • Species reactivity

    Reacts with: Human
  • Immunogen

    Recombinant fragment within Human KMT2A/ MLL aa 1550-1800. The exact sequence is proprietary.
    Database link: Q03164

  • Positive control

    • WB: Wild-type HAP1 whole, KMT2A/MLL knockout HAP1 whole and HeLa lysates.
  • General notes

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.



Our Abpromise guarantee covers the use of ab234435 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000.
  • Application notes
    Is unsuitable for Flow Cyt,ICC/IF,IHC-P or IP.
  • Target

    • Function

      Histone methyltransferase that plays an essential role in early development and hematopoiesis. Catalytic subunit of the MLL1/MLL complex, a multiprotein complex that mediates both methylation of 'Lys-4' of histone H3 (H3K4me) complex and acetylation of 'Lys-16' of histone H4 (H4K16ac). In the MLL1/MLL complex, it specifically mediates H3K4me, a specific tag for epigenetic transcriptional activation. Has weak methyltransferase activity by itself, and requires other component of the MLL1/MLL complex to obtain full methyltransferase activity. Has no activity toward histone H3 phosphorylated on 'Thr-3', less activity toward H3 dimethylated on 'Arg-8' or 'Lys-9', while it has higher activity toward H3 acetylated on 'Lys-9'. Required for transcriptional activation of HOXA9. Promotes PPP1R15A-induced apoptosis.
    • Tissue specificity

      Heart, lung, brain and T- and B-lymphocytes.
    • Involvement in disease

      Note=Chromosomal aberrations involving MLL are a cause of acute leukemias. Translocation t(1;11)(q21;q23) with MLLT11/AF1Q; translocation t(3;11)(p21;q23) with NCKIPSD/AF3p21; translocation t(3,11)(q25,q23) with GMPS; translocation t(4;11)(q21;q23) with AFF1/MLLT2/AF4; insertion ins(5;11)(q31;q13q23) with AFF4/AF5Q31; translocation t(5;11)(q12;q23) with AF5-alpha/CENPK; translocation t(6;11)(q27;q23) with MLLT4/AF6; translocation t(9;11)(p22;q23) with MLLT3/AF9; translocation t(10;11)(p11.2;q23) with ABI1; translocation t(10;11)(p12;q23) with MLLT10/AF10; t(11;15)(q23;q14) with CASC5 and ZFYVE19; translocation t(11;17)(q23;q21) with MLLT6/AF17; translocation t(11;19)(q23;p13.3) with ELL; translocation t(11;19)(q23;p13.3) with MLLT1/ENL; translocation t(11;19)(q23;p23) with GAS7; translocation t(X;11)(q13;q23) with FOXO4/AFX1. Translocation t(3;11)(q28;q23) with LPP. Translocation t(10;11)(q22;q23) with TET1. Translocation t(9;11)(q34;q23) with DAB2IP. Translocation t(4;11)(p12;q23) with FRYL. Fusion proteins MLL-MLLT1, MLL-MLLT3 and MLL-ELL interact with PPP1R15A and, on the contrary to unfused MLL, inhibit PPP1R15A-induced apoptosis.
      Note=A chromosomal aberration involving MLL may be a cause of chronic neutrophilic leukemia. Translocation t(4;11)(q21;q23) with SEPT11.
    • Sequence similarities

      Belongs to the histone-lysine methyltransferase family. TRX/MLL subfamily.
      Contains 3 A.T hook DNA-binding domains.
      Contains 1 bromo domain.
      Contains 1 CXXC-type zinc finger.
      Contains 1 FY-rich C-terminal domain.
      Contains 1 FY-rich N-terminal domain.
      Contains 3 PHD-type zinc fingers.
      Contains 1 post-SET domain.
      Contains 1 SET domain.
    • Domain

      the 9aaTAD motif is a transactivation domain present in a large number of yeast and animal transcription factors.
      The SET domain structure is atypical and is not in an optimal position to have methyltransferase activity. It requires other components of the MLL1/MLL complex, such as ASH2L or RBBP5, to order the active site and obtain optimal histone methyltransferase activity.
      The CXXC-type zinc finger binds bind to nonmethyl-CpG dinucleotides.
    • Post-translational

      Proteolytic cleavage by TASP1 generates MLL cleavage product N320 and MLL cleavage product C180, which reassemble through a non-covalent association. 2 cleavage sites exist, cleavage site 1 (CS1) and cleavage site 2 (CS2), to generate MLL cleavage products N320 and C180. CS2 is the major site.
    • Cellular localization

      Nucleus and Nucleus. Localizes to a diffuse nuclear pattern when not associated with MLL cleavage product N320.
    • Information by UniProt
    • Database links

    • Alternative names

      • ALL-1 antibody
      • ALL1 antibody
      • C-terminal cleavage product of 180 kDa antibody
      • CXXC-type zinc finger protein 7 antibody
      • CXXC7 antibody
      • HRX antibody
      • HTRX1 antibody
      • KMT2A antibody
      • Lysine N-methyltransferase 2A antibody
      • Mll antibody
      • MLL cleavage product C180 antibody
      • MLL1 antibody
      • MLL1_HUMAN antibody
      • MLL1A antibody
      • N-terminal cleavage product of 320 kDa antibody
      • p180 antibody
      • p320 antibody
      • Trithorax-like protein antibody
      • TRX1 antibody
      • Zinc finger protein HRX antibody
      see all


    • Anti-KMT2A / MLL antibody [EPR22647-8] (ab234435) at 1/1000 dilution + HeLa (human cervix adenocarcinoma epithelial cell), whole cell lysate at 40 µg

      Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution

      Observed band size: 320 kDa
      why is the actual band size different from the predicted?

      Blocking and Dilution Buffer and concentration: 5% NFDM/TBST.

      The molecular weight observed is consistent with what has been described in the literature (PMID: 12482972) This antibody reacts with an unidentifiable protein below 315 kDa.

      Exposure time: 5.5 seconds

    • All lanes : Anti-KMT2A / MLL antibody [EPR22647-8] (ab234435) at 1/1000 dilution

      Lane 1 : Wild-type HAP1 whole cell lysate
      Lane 2 : KMT2A/MLL knockout HAP1 whole cell lysate

      Lysates/proteins at 20 µg per lane.

      All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution

      Observed band size: 320 kDa why is the actual band size different from the predicted?

      Blocking and Dilution Buffer and concentration: 5% NFDM/TBST.

      The molecular weight observed is consistent with what has been described in the literature (PMID: 12482972). This antibody reacts with unidentifiable proteins below 315 kDa.  ab234435 was shown to specifically react with KMT2A/MLL in wild-type HAP1 cells as signal was lost in KMT2A/MLL knockout cells. Wild-type and KMT2A/MLL knockout samples were subjected to SDS-PAGE. ab234435 and ab181602 (Rabbit anti-GAPDH loading control) were incubated 1 hour at room temperature at 1/1000 dilution and 1/200,000 dilution respectively. Blots were developed with Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051) secondary antibody at 1/100,000 dilution for 1 hour at room temperature before imaging. The blot was developed on a BIO-RAD® ChemiDoc™ MP instrument using the ECL technique.

      Exposure time: 48 seconds


    ab234435 has not yet been referenced specifically in any publications.

    Customer reviews and Q&As

    There are currently no Customer reviews or Questions for ab234435.
    Please use the links above to contact us or submit feedback about this product.

    For licensing inquiries, please contact partnerships@abcam.com

    Sign up